The Cancer Letter

Inside information on cancer research and drug development

NCI Trials

NCI Trials for May

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.

Phase 1 – 10187

A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell Carcinoma

National Heart Lung and Blood Institute
Childs, Richard W.
(301) 451-7128

Phase II – EA9171

Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

ECOG-ACRIN Cancer Research Group
Zeidan, Amer M.
(203) 737-2572

Phase II – NRG-GU006

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer

NRG Oncology
Feng, Felix Yi-Chung
(415) 353-7183

Phase III – CCTG MA.39

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Canadian Cancer Trials Group
Whelan, Timothy Joseph
(905) 387-9711

Phase Other – ANBL17B5-Q

Growth Factor Receptor Trafficking and Neuroblastoma Differentiation

Children’s Oncology Group
Zage, Peter Eric
(858) 534-6494

Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthConversation with The Cancer Letter

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

By Jacquelyn Cobb
Guest Editorial

Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

By Harpreet Singh
Sponsored

Advancing pediatric oncology and survivorship: A research vision at City of Hope

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.
By Saro Armenian
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account